Medicare Bridge Program · Starting July 1, 2026

Wegovy vs Zepbound for Medicare patients.

Wegovy® (semaglutide) and Zepbound® (tirzepatide) are both highly effective medications for chronic weight management. While earlier studies suggested greater average weight loss with Zepbound, the approval of the higher-dose 7.2 mg Wegovy pen has narrowed that difference considerably. Today, the best medication often depends less on average study results and more on your medical history, treatment goals, side-effect profile, insurance coverage, and personal preferences.

Here’s how Wegovy and Zepbound compare, so you can be prepared when you meet with your provider.

Back to all guides

The short version

For many patients, either medication can be an excellent choice. Average weight-loss results at the highest approved doses are now remarkably similar, and the best medication depends on your medical history, treatment goals, side-effect profile, and Medicare coverage.

Side by side

The facts, compared.

AttributeWegovy®Zepbound®
ManufacturerNovo NordiskEli Lilly
Active ingredientSemaglutideTirzepatide
How it worksGLP-1 receptor agonistDual GIP + GLP-1 receptor agonist
DeliveryWeekly self-injectionWeekly self-injection
FDA-approved for chronic weight managementYes (2021)Yes (2023)
Average weight loss in clinical trials*~18–21% of body weight with the 7.2 mg dose (72 weeks)~18–22% of body weight (72 weeks)
Cost under the Medicare Bridge Program**$50 / month flat$50 / month flat

*Average weight loss reflects results from manufacturer-sponsored Phase 3 clinical trials at the highest approved doses. Cross-trial comparisons have limitations, and individual results vary.
**$50/month pricing reflects the federal Medicare GLP-1 Bridge Program launching July 1, 2026 for qualifying beneficiaries. Eligibility is determined clinically.

Which medication is right for you?

Which medication is right for you?

For many patients, either medication can be an excellent choice. While average weight-loss results are now remarkably similar at the highest approved doses, no medication is right for everyone. During your consultation, we'll review your health history, Medicare coverage options, lifestyle, and goals to determine which treatment is the best fit for you.

01

Mechanism of action

Wegovy is a single-pathway GLP-1 agonist. Zepbound activates both GLP-1 and GIP receptors. The dual mechanism may offer additional metabolic benefit for some patients, though average weight loss at the highest approved doses is now similar between the two medications.

02

Side-effect tolerance

Both medications commonly cause nausea, constipation, and reduced appetite early in dosing. Some patients tolerate one significantly better than the other. The right choice is often the one your body adjusts to without disrupting nutrition and hydration.

03

Existing conditions and medications

Personal and family history of medullary thyroid cancer, pancreatitis, severe gastrointestinal conditions, and certain medications impact if GLP-1 medications are appropriate. This is the part that will be discussed between the patient and their provider.

04

Muscle preservation and healthy aging

For Medicare-age patients especially, the goal isn't maximum weight loss — it's metabolic health that protects muscle mass, mobility, and independence. The medication is one tool inside a broader plan.

A note before you decide.

This page is educational, not medical advice. The right medication — or whether a GLP-1 is right for you at all — is a clinical decision that depends on your full health history.

  • Both medications are FDA-approved for chronic weight management in adults meeting specific BMI criteria.
  • Neither is a substitute for nutrition, sleep, strength training, or addressing underlying metabolic drivers.
  • Both require ongoing clinical oversight — including monitoring for muscle loss, nutritional gaps, and side effects.
Related guides

Keep reading.